A Deep Dive into the Small-Cap Pioneer's Latest Moves, Including a -0.42% Impact from Exiting a Major StakeCharles M. Royce, a pioneer of small-cap investing an
Annual report highlights commitment to meeting customer needs and the company's record-setting safety performance PITTSBURGH, Aug. 12, 2026 /PRNewswire/ -- MSA Safety Incorporated (NYSE: MSA), a global leader in advanced safety products and solutions, today released its 2025 Impact Report, underscoring continued progress across its three strategic pillars – Products & Solutions, People and Planet – while also delivering its strongest safety performance to date. Record Safety Performance Reflects Deeply Embedded Culture MSA achieved its strongest safety results on record, reinforcing its long-standing commitment to safeguarding employees across its global operations.
PITTSBURGH, Aug. 3, 2026 /PRNewswire/ -- The Board of Directors of MSA Safety Incorporated (NYSE: MSA) today declared a third quarter dividend of $0.54 per share on common stock, payable September 10, 2026, to shareholders of record on August 14, 2026. The Board also declared a dividend of $0.5625 per share on preferred stock, payable September 1, 2026, to shareholders of record on August 14, 2026.
MSA Safety Incorporporated NYSE: MSA reported higher second-quarter sales, earnings and cash flow, while maintaining its outlook for mid-single-digit organic growth in 2026. The company also said it completed its acquisition of Autronica Fire and Security in early July.
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported imaging results from the third patient with multiple system atrophy (MSA) to complete dosing in its ongoing Phase 2 clinical trial of intranasal foralumab, with PET scans showing reductions in brain inflammation following treatment. The company said quantitative analysis of PET imaging demonstrated reductions in inflammatory activity in brain regions commonly affected by MSA, including the basal ganglia and cerebellar white matter.